GEN Exclusives

More »

GEN News Highlights

More »
Sep 7, 2011

BioLineRx Gains Rights to Antipain Candidate from Tel Aviv University

  • BioLineRx signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University for the development and commercialization of BL-7050, an orally available treatment for neuropathic and inflammatory pain.

    BL-7050 is based on technology developed in the laboratory of Bernard Attali, Ph.D., from the department of physiology and pharmacology, the Sackler faculty of medicine at Tel Aviv University. It is an NCE based on the molecular structure of diclofenac (Voltaren), a well-known nonsteroidal anti-inflammatory drug used for the treatment of nociceptive and inflammatory pain.

    BL-7050 reportedly operates via a novel mechanism of action, though, namely opening specific potassium channels in nerve cells. The opening of these channels reduces the activity of the nerve cells, thereby reducing or preventing pain signals. Preclinical trials in cell culture and in animal models have shown that the molecule is effective at reducing neuronal activity and pain levels, according to BioLineRx. It also has an improved safely profile, the firm adds.

    BioLineRx’ pipeline currently consists of five clinical-stage candidates: BL-1020 for schizophrenia is in Phase II/III trials; BL-1040 for treatment of patients following a myocardial infarction has completed a Phase I/II study and has been out-licensed to Ikaria in a deal valued at $282.5 million plus sales royalties; BL-5010 for nonsurgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development; and BL-7040 for treating inflammatory bowel disease has completed Phase I.

    The company has nine candidates in various stages of preclinical development for a variety of indications including central nervous system diseases, oncology, infectious diseases, as well as cardiovascular and autoimmune diseases.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?